Mitapivat

• The Effect of Mitapivat on Cerebral Perfusion and Oxygen Metabolism in Sickle Cell Disease Pending
  2024-513528-41-02 Phase III 1 country Amsterdam UMC Stichting
• Clinical study to check the Efficacy and Safety of Mitapivat in Patients with Sickle Cell Disease Pending
  2024-515202-84-00 Phase II/III 5 countries Agios Pharmaceuticals Inc.
• Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Ki… Recruiting
  2024-515025-28-00 Phase III 5 countries Agios Pharmaceuticals Inc.
• Mitapivat in Membranopathies Recruiting
  2023-503271-24-01 Phase II 2 countries Eurobloodnet Association
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended
  2024-512747-23-00 Phase III 8 countries Agios Pharmaceuticals Inc.
• Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Ki… Ended
  2024-515024-37-00 Phase III 4 countries Agios Pharmaceuticals Inc.
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended
  2024-512745-16-00 Phase III 7 countries Agios Pharmaceuticals Inc.
• A study of mitapivat in sickle cell disease Ended
  2024-515569-32-00 Phase II 1 country Julius Clinical Research B.V.
• A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease Ended
  2023-510289-28-00 Phase II 2 countries Agios Pharmaceuticals Inc.

Showing 1–9 of 9 trials